See No Evil

Partnership also includes an agreement for Arvinas to sell its preclinical AR-V7 program to Novartis.

In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.

Pharma companies and RPM manufacturers must work together to find solutions to make DCT more commonly available.

Ian Baer, Founder and Chief Soothsayer, Sooth, discusses how pharmaceutical companies and healthcare advertising agencies can adapt their strategies to attract Gen-Z.

The takeover is contingent upon a minimum acceptance rate of 65% and other conditions outlined in the offer document.

Leverage priorities in preclinical business planning.